Status:
RECRUITING
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
Lead Sponsor:
Hunan Cancer Hospital
Conditions:
Cancer
FAP
Eligibility:
All Genders
18-90 years
Brief Summary
To evaluate the potential usefulness of 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging （PET/MR）for the diagnosis of p...
Detailed Description
Subjects with various types of cancer underwent 18F-FAPI-04 PET/CT and PET/MR imaging either for an initial assessment, recurrence detection or assessment of pathologic response. Tumor uptake was quan...
Eligibility Criteria
Inclusion
- patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion
- patients with non-malignant lesions; patients with pregnancy; the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06557590
Start Date
January 1 2024
End Date
December 31 2028
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer hospital
Changsha, Hunan, China, 410000